- Oops!Something went wrong.Please try again later.
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the launch of version 6.1 of BioDiscovery’s NxClinical software with expanded capabilities for next-generation sequencing (NGS) data in genetic diseases and cancer. NxClinical is an industry-leading, platform-agnostic software solution, which integrates NGS and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants (CNV), single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
“This new version is designed to address requests from our NxClinical customers around the world seeking to see more of what matters in their NGS data,” commented Soheil Shams, PhD, Chief Informatics Officer of Bionano Genomics. “We are committed to helping customers reveal more clinically relevant variants from genomic data across multiple platforms with a streamlined workflow that can allow for optimal turnaround time. This software upgrade represents another step further as we continue toward laying the groundwork for our goal of integrating OGM data with NGS data to provide what we believe can become the most comprehensive view of genome variation.”
We believe version 6.1 significantly improves the ability of NxClinical to detect more clinically relevant variants from NGS data with the inclusion of uniparental disomy functionality and the expanded sequence knowledgebase for visualization and reporting of relevant genomic variants. In addition, data interpretation has been streamlined with the automated annotation of clinically relevant variants using the American College of Medical Genetics and Genomics (ACMG) technical standards. This feature automatically calculates the relevance for many of the evidence categories described by the ACMG technical standards for CNV interpretation, which can simplify data interpretation and reduce time to reportable result.
“At Bionano, we are working to transform the way the world sees the genome to elevate human health and wellness,” said Erik Holmlin, PhD, President and CEO of Bionano Genomics. “Software is the primary way our customers interact with their data and experience our products. Our goal is to increase the number of Bionano subscribers using NxClinical software to create a network effect where customers can obtain more meaningful results from their NGS and microarray data today so that in the future they can more easily implement OGM within the same software tool to see more genomic variants that matter.”
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability and utility of NxClinical software to help visualize, interpret and report NGS data in genetic diseases and cancer; the ability of NxClinical software to integrate OGM data with NGS data to provide a comprehensive view of genome variation; the ability of NxClinical software to create a network effect that combines the synergies of NGS and microarray data to allow implementation of OGM within the same software. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; failure of the new version of NxClinical to perform as intended; the effect on our software of cyber attacks, viruses and the like; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
+1 (858) 366-3243
+1 (503) 799-7520